| Hans-Günter Meyer-Thompson | Amphetamine
USA. MDMA Advances Another Step As Tool to Treat PTSD - 3,4-methylenedioxymethamphetamine (MDMA) holds promise to once again become a therapeutic tool.
After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential “breakthrough therapy” for treatment of posttraumatic stress disorder (PTSD). (American Psychiatric Association, 20.10.2017)
http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.pp10b6